Literature DB >> 8917368

Influence of antimalarials chloroquine, quinine, primaquine and mepacrine on the evolution of Ehrlich ascites tumour.

M Castelli1, G Baggio, A I Ruberto, A Tampieri, P L Tartoni, T Rossi, M R Bossa, I Galatulas.   

Abstract

Substances like imidazoles, benzimidazoles and also quinolines, whose chemical structure includes a heterocyclic nitrogen, are known to interfere with the microsomal oxidation and, in some cases, with the metabolism of drugs. Since chloroquine and primaquine exert this effect in vivo and in vitro, we studied the influence of other antimalarials (quinine and mepacrine) in mice with induced Ehrlich ascites tumour (EAT) to find out whether variations in oxygen consumption affected the course of the disease. In vitro data, obtained by a polarographic technique, indicate that primaquine and, in particular, mepacrine increase EAT-cell oxygen consumption, while in vivo data, obtained in mice injected with an inoculum of about 1 x 10(6) tumour cells per mouse, show that both drugs, but notably mepacrine, accelerate tumour growth, as monitored by Cox's statistical method for body weight, and lead to earlier death. In cases of existing neoplasia, therefore, the potentially toxic effects of certain antimalarials must be borne in mind.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8917368

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

Authors:  Reza Ehsanian; Carter Van Waes; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2011-05-15       Impact factor: 5.712

2.  Chloroquine commonly induces hormetic dose responses.

Authors:  Edward J Calabrese; Jaap C Hanekamp; Yannic N Hanekamp; Rachna Kapoor; Gaurav Dhawan; Evgenios Agathokleous
Journal:  Sci Total Environ       Date:  2020-09-25       Impact factor: 7.963

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.